Efficacy Study Of Tofacitinib In Pediatric JIA Population
- Registry ID
- EUCTR2015-001438-46
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Pfizer Inc.
- Start date
- 2018-01-08
- Completion date
- 2019-05-16
- Last update
- 2026-08-16
Conditions
- JUVENILE IDIOPATHIC ARTHRITIS (JIA)
Summary
To compare the efficacy of tofacitinib versus placebo for the treatment of signs and symptoms of JIA at Week 44/End of Study (Week 26 of the double-blind phase) as measured by the percentage of subjects with disease flare (according to PRCSG/PRINTO Disease Flare criteria) after Week 18 of the open-label run-in phase.
Locations
- , , Poland
- , , Germany
- , , Belgium
- , , UK
- , , Spain
Related clinical trials
- AN OPEN-LABEL MULTIPLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF UPADACITINIB IN PEDIATRIC SUBJECTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
- AN OPEN-LABEL, SEQUENTIAL, ASCENDING, REPEATED DOSE-FINDING STUDY OF SARILUMAB, ADMINISTERED WITH SUBCUTANEOUS (SC) INJECTION, IN CHILDREN AND ADOLESCENTS, AGED 1 TO 17 YEARS, WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA), FOLLOWED BY AN EXTENSION PHASE
- A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
- A MULTICENTER, OPEN-LABEL TRIAL OF INTRAVENOUS GOLIMUMAB A HUMAN ANTI-TNFA ANTIBODY, IN PEDIATRIC SUBJECTS WITH ACTIVE POLYARTICULAR COURSE JUVENILE IDIOPATHIS ARTHRITIS DESPITE METHOTREXATE THERAPY
- B-SPECIFIC 4 PATIENTS: STUDY OF PEDIATRIC EFFICACY AND SAFETY WITH FIRST-LINE USE OF CANAKINUMAB: AN OPEN-LABEL CANAKINUMAB (ACZ885) DOSE REDUCTION OR DOSE INTERVAL PROLONGATION EFFICACY AND SAFETY STUDY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
- "A PHASE IB, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMIS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS."
View on source registry